Oncology Brothers: Practice-Changing Cancer Discussions

By Oncology BrothersMedicine Health & Fitness

Oncology Brothers: Practice-Changing Cancer Discussions episodes

October 22Multiple Myeloma CAR-T Management - Partners in Practice
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of second-line treatment options for multiple myeloma, with a special focus on CAR T-cell therapy. Joined by experts Dr. Rafael Fonseca, a multiple myeloma specialist from the Mayo Clinic; Dr. Beth Faiman, a nurse practitioner specializing in myeloma; and Ms. Carrie Bellerive, a clinical nurse coordinator at Memorial Sloan Kettering Cancer Center, the discussion covers:
The eligibility criteria for CAR T-cell therapy and the data supporting its effectiveness
Insights from recent clinical trials, including CARTITUDE-1 and CARTITUDE-2, highlighting long-term outcomes and potential for cure
The importance of patient preparation and shared decision-making in treatment planning
The role of bridging therapy and the significance of managing disease burden prior to CAR T-cell infusion
An overview of acute and chronic side effects associated with CAR T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity
The critical coordination efforts behind the scenes to ensure seamless patient care

Join us as we explore how collaboration among healthcare professionals can enhance patient outcomes in the evolving landscape of multiple myeloma treatment.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Don't forget to like, subscribe, and share your thoughts in the comments!

#MultipleMyeloma, #CARTtherapy, #BridgingTherapy, #HoldingTherapy, #OncologyBrothers
26 min
October 19CAR-T Cell Therapy in Multiple Myeloma & Lymphoma - Clinical Foundations
Welcome to the Oncology Brothers podcast! In this episode, we dived into the world of CAR T-cell therapy, featuring insights from hematology experts Drs. Luciano Costa and Shernan Holtan.

Join us as we explore:
The basics of CAR T-cell therapy and the patient journey from referral to infusion
The approved indications for CAR T-cell therapy in multiple myeloma and lymphoma, including the differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel)
The importance of holding and bridging therapies to optimize patient outcomes
The evolving landscape of side effects associated with CAR T-cell therapy, including acute and chronic effects
Strategies for community oncologists to better manage patient care and improve access to CAR T-cell therapies

With the potential for curative outcomes in myeloma and lymphoma, understanding these therapies is crucial for both patients and healthcare providers. Tune in for an informative discussion that aims to bridge the gap between community oncology and specialized care.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
•⁠ ⁠X/Twitter: https://x.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest advancements in cancer treatment!
#CARTtherapy, #MultipleMyeloma, #Lymphoma, #BridgingTherapy, #OncologyBrothers
23 min
October 12Rapid Fire Rounds - Thrombocytopenia Workup & Management with Dr. Ronak Mistry
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Ronak Mistry, a hematologist from Penn Medicine, for a rapid-fire round addressing common questions about thrombocytopenia.

We dived into a variety of topics, including:
Differentiating between inherited thrombocytopenia and mild immune thrombocytopenia (ITP)
The role of steroids and bone marrow biopsy in diagnosis
Management of anticoagulation in patients with low platelet counts
Key distinctions between ITP, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP)
Recent updates to ITP guidelines and the incorporation of new treatment options
Thrombocytopenia in pregnancy and its management
Treatment options for chemotherapy-induced thrombocytopenia
Common medications that may contribute to thrombocytopenia

Join us as we explore these important topics and provide practical insights for healthcare professionals dealing with thrombocytopenia in their clinical practice.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#Thrombocytopenia, #ITP, #TTP, #aHUS, #OncologyBrothers
28 min
October 08Challenging Cases in Small Cell Lung Cancer (SCLC) - Drs. Estela Rodriguez & Misty Shields
In this episode of the Oncology Brothers podcast, we dived into two challenging cases of small cell lung cancer (SCLC) to explore the latest supportive care options, the role of prophylactic cranial irradiation (PCI), and the sequencing of available treatments.

We were joined by Dr. Estela Rodriguez from the University of Miami and Dr. Misty Shields from the Indiana University, as they discussed:
A young woman with limited-stage SCLC undergoing concurrent chemotherapy and radiation, and the management of treatment-related cytopenias
The implications of the recent MAVERICK trial comparing MRI surveillance to PCI and its impact on patient care
The evolving landscape of treatment options, including the use of trilaciclib and promising new therapies like tarlatamab and antibody-drug conjugates (ADCs)
Insights into maintenance therapy and the importance of close monitoring for brain metastases

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the management of small cell lung cancer.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer care!
#SmallCellLungCancer, #SCLC, #SupportiveCare, #MAVERICKtrial, #OncologyBrothers
19 min
October 05WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, to discuss key studies presented at the World Conference on Lung Cancer 2026.

We dived into five pivotal studies, including:
MAVERICK: study on the role of MRI surveillance in small cell lung cancer (SCLC), showing that prophylactic cranial irradiation (PCI) may no longer be necessary
ADAURA Update: 8-year update continues to show benefit of adjuvant osimertinib for early-stage EGFR-mutant lung cancer, with an impressive overall survival (OS) benefit
HARMONi: potential of ivonescimab, a PD-1 and VEGF bispecific antibody, in the treatment of EGFR-positive disease after progression on third-generation therapies
PAPILLON: discussion on the frontline treatment options for EGFR exon 20 insertion mutations, including the role of amivantamab and the anticipated approval of sunvozertinib
DESTINY-Lung04: an analysis of trastuzumab deruxtecan (T-DXd) in HER2-mutated lung cancer and its implications for treatment strategies

Join us as we explore the latest advancements in lung cancer treatment and the importance of biomarker testing. Don't miss this informative episode packed with insights for oncologists and healthcare professionals!

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Subscribe for more updates and discussions on the latest in oncology research and practice!

#LungCancer, #WCLC2026, #Osimertinib, #Ivonescimab, #MAVERICK, #PAPILLON, #TDXd, #OncologyBrothers
20 min
September 30Managing Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab
Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.

Join us as we discussed:
The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma
The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions
Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind
The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes

We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes!

#HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers
22 min
September 28Upper GI Treatment Algorithm (Esophageal, Gastric, GEJ) - Dr. Sam Klempner
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.

During our discussion we touched on:
The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments
The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery
The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease
The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression
The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies
Management of side effects associated with these therapies and the importance of patient quality of life

Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#UpperGICancer, #GastricCancer, #Zanidatamab, #Zolbetuximab, #OncologyBrothers
27 min
September 24Follicular & Mantle Cell Lymphoma Treatment Algorithm: Dr. Jonathan Friedberg
In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma.

Join us as we explored:
The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging
Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches
The evolving role of maintenance therapy and what recent studies have shown about progression-free and overall survival
New treatment options in relapsed/refractory follicular lymphoma, including tafasitamab and epcoritamab
The importance of TP53 testing in mantle cell lymphoma and the evolving role of BTK inhibitors in frontline treatment
The role of CAR T-cell therapy and bispecific antibodies in the evolving lymphoma treatment landscape

This discussion provided practical insights into current treatment algorithms and emerging strategies for patients with follicular lymphoma and mantle cell lymphoma.

Whether you're a hematologist, oncologist, advanced practice provider, nurse, pharmacist, trainee, or healthcare professional interested in lymphoma care, this episode offers an expert perspective on the rapidly evolving treatment landscape.

If you found this discussion valuable, please like the video, subscribe to the Oncology Brothers, and share your thoughts in the comments.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Subscribe for more expert discussions on hematology, oncology, lymphoma, immunotherapy, cellular therapy, targeted therapy, and advances in cancer care.
#FollicularLymphoma #MantleCellLymphoma #Lymphoma #Hematology #OncologyBrothers
23 min
September 22Diffuse Large B-cell Lymphoma (DLBCL) Treatment Algorithm: Dr. Mazyar Shadman
In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.

We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies.

Key topics covered in this episode:
Frontline treatment options for DLBCL
The role of polatuzumab in early-stage disease
Treatment paradigms for advanced-stage DLBCL
CAR T-cell therapy: who should receive it and when
The importance of community and tertiary care partnerships in improving patient access to innovative therapies

Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
X/Twitter: https://x.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and share your thoughts in the comments!
#DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers
22 min
September 21Revolution Medicines CEO Dr. Mark Goldsmith: Daraxonrasib dream to reality
Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib.

Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes.

Keypoints:
Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a mutation present in over 90% of cases.
The drug's development represents a major shift in pancreatic cancer, moving from a historically untreatable disease to a promising target for precision medicine.
Early clinical trial results demonstrated remarkable tumor shrinkage, driving urgency to bring the therapy to patients.
Management of side effects, including rash and gastrointestinal issues, is essential for optimal patient outcomes.
Ensuring patient access—despite high treatment costs—remains a priority, with patient assistance programs and insurance navigation support in place.
Future directions include combination therapies and the goal of transforming pancreatic cancer into a manageable chronic disease.

We discussed the critical gaps between academic research and community practice, the importance of understanding side effects, and the financial implications of new therapies. Dr. Goldsmith also highlighted the future of pancreatic cancer treatment and the ongoing commitment to improving patient care.

Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights and information.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer treatment and research!

#PancreaticCancer, #Daraxonrasib, #RASinhibitor, #DrugDevelopment, #OncologyBrothers
27 min

About Oncology Brothers: Practice-Changing Cancer Discussions

From the publisher's feed

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.

Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.

Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.

Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.

If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at [email protected]